Terms: = Kidney tumors AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Treatment
68 results:
1. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
[TBL] [Abstract] [Full Text] [Related]
2. Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach.
Xie S; Fang Y; Yang Y; Liu L; Bai J; Lin S; Zhang B; Fang Y
Eur J Pediatr; 2024 Feb; 183(2):557-567. PubMed ID: 38019286
[TBL] [Abstract] [Full Text] [Related]
3. The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database.
Koguchi T; Naito S; Hatakeyama S; Numakura K; Muto Y; Kato R; Kojima T; Kawasaki Y; Morozumi K; Kandori S; Kawamura S; Nishiyama H; Ito A; Habuchi T; Obara W; Ohyama C; Tsuchiya N; Kojima Y
Cancer Med; 2023 Nov; 12(22):20677-20689. PubMed ID: 37905674
[TBL] [Abstract] [Full Text] [Related]
4. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.
Dizman N; Govindarajan A; Zengin ZB; Meza L; Tripathi N; Sayegh N; Castro DV; Chan EH; Lee KO; Prajapati S; Feng M; Loo V; Pace M; O'Brien S; Bailey E; Barragan-Carrillo R; Chehrazi-Raffle A; Hsu J; Li X; Agarwal N; Pal SK
Clin Genitourin Cancer; 2023 Oct; 21(5):530-536. PubMed ID: 37495481
[TBL] [Abstract] [Full Text] [Related]
5. Metastases to the kidney from primary lung cancer : clinicopathological analysis of six cases in a single center.
Lian H; Pan X; Hong B; Min J; Huang F
Diagn Pathol; 2023 May; 18(1):60. PubMed ID: 37161448
[TBL] [Abstract] [Full Text] [Related]
6. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
[TBL] [Abstract] [Full Text] [Related]
7. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.
Le BK; McGarrah P; Paciorek A; Mohamed A; Apolo AB; Chan DL; Reidy-Lagunes D; Hauser H; Rivero JD; Whitman J; Batty K; Zhang L; Raj N; Le T; Bergsland E; Halfdanarson TR
Clin Genitourin Cancer; 2023 Jun; 21(3):403-414.e5. PubMed ID: 37031047
[TBL] [Abstract] [Full Text] [Related]
8. Markers of local kidney cancer recurrence: A surgeon's mistake or a pattern? Review.
Gaas MY; Kaprin AD; Vorobyev NV; Rapoport LM; Korolev DO; Kalpinsky AS
Urologia; 2023 Aug; 90(3):459-469. PubMed ID: 36515572
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
Sheng X; Ye D; Zhou A; Yao X; Luo H; He Z; Wang Z; Zhao Y; Ji Z; Zou Q; He C; Guo J; Tu X; Liu Z; Shi B; Liu B; Chen P; Wei Q; Hu Z; Zhang Y; Jiang K; Zhou F; Wu D; Fu C; Li X; Wu B; Wang L; Qin S; Li G; Liu Y; Guo H; Chen K; Zhang D; Wang G; Ding L; Wang Y; Yuan X; Guo J
Eur J Cancer; 2023 Jan; 178():205-215. PubMed ID: 36459768
[TBL] [Abstract] [Full Text] [Related]
10. Collecting duct carcinoma: Epidemiology, clinical characteristics and survival.
Panunzio A; Tappero S; Hohenhorst L; Cano Garcia C; Piccinelli M; Barletta F; Tian Z; Tafuri A; Briganti A; De Cobelli O; Chun FKH; Tilki D; Terrone C; Kapoor A; Saad F; Shariat SF; Cerruto MA; Antonelli A; Karakiewicz PI
Urol Oncol; 2023 Feb; 41(2):110.e7-110.e14. PubMed ID: 36456452
[TBL] [Abstract] [Full Text] [Related]
11. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract] [Full Text] [Related]
12. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group kidney Cancer Consortium (TKCC) Database.
Yekedüz E; Karakaya S; Ertürk İ; Tural D; Uçar G; Şentürk Öztaş N; Arıkan R; Hızal M; Küçükarda A; Sever ÖN; Arslan Ç; Can O; Kılıçkap S; Yazgan C; Karadurmuş N; Şendur MA; Çiçin İ; Demirci U; Özgüroğlu M; Öksüzoğlu B; Ürün Y
Clin Genitourin Cancer; 2023 Feb; 21(1):175-182. PubMed ID: 35970759
[TBL] [Abstract] [Full Text] [Related]
13. The clinical significance, immune infiltration, and tumor mutational burden of angiogenesis-associated lncRNAs in kidney renal clear cell carcinoma.
Zhang W; Liu Z; Wang J; Geng B; Hou W; Zhao E; Li X
Front Immunol; 2022; 13():934387. PubMed ID: 35958561
[TBL] [Abstract] [Full Text] [Related]
14. CABOSEQ: The Effectiveness of Cabozantinib in Patients With treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Navani V; Wells JC; Boyne DJ; Cheung WY; Brenner DM; McGregor BA; Labaki C; Schmidt AL; McKay RR; Meza L; Pal SK; Donskov F; Beuselinck B; Otiato M; Ludwig L; Powles T; Szabados BE; Choueiri TK; Heng DYC
Clin Genitourin Cancer; 2023 Feb; 21(1):106.e1-106.e8. PubMed ID: 35945133
[TBL] [Abstract] [Full Text] [Related]
15. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract] [Full Text] [Related]
16. Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis.
Wang N; Qin Y; Du F; Wang X; Song C
Gene; 2022 Aug; 834():146638. PubMed ID: 35680019
[TBL] [Abstract] [Full Text] [Related]
17. Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors.
Nuzzo PV; Adib E; Weise N; Curran C; Stewart T; Freeman D; Nassar AH; Abou Alaiwi S; Bakouny Z; McGregor BA; Choueiri TK; Jain RK; McKay RR; Sonpavde G
Clin Genitourin Cancer; 2022 Aug; 20(4):301-306. PubMed ID: 35614012
[TBL] [Abstract] [Full Text] [Related]
18. Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic kidney Cancer (SURTIME) trial.
Abu-Ghanem Y; van Thienen JV; Blank C; Aarts MJB; Jewett M; de Jong IJ; Lattouf JB; van Melick HHE; Wood L; Mulders P; Rottey S; Wagstaff J; Zondervan P; Powles T; Neven A; Collette L; Tombal B; Haanen J; Bex A
BJU Int; 2022 Jul; 130(1):68-75. PubMed ID: 34706141
[TBL] [Abstract] [Full Text] [Related]
19. Activity of Systemic treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
Cerbone L; Nunno VD; Carril Ajuria L; Alves Costa Silva C; Colomba E; Guida A; Salviat F; Hirsch L; Benchimol-Zouari A; Flippot R; Escudier B; Albiges L
Clin Genitourin Cancer; 2022 Feb; 20(1):80-87. PubMed ID: 34688544
[TBL] [Abstract] [Full Text] [Related]
20. Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kaneko H; Tajima Y; Oya M
Jpn J Clin Oncol; 2021 Nov; 51(11):1656-1664. PubMed ID: 34350454
[TBL] [Abstract] [Full Text] [Related]
[Next]
